Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in AI Re-Scored HER2-Ultralow Breast Cancer
NCT07782086Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in breast cancer. Primary endpoint: Objective Response Rate up to 36 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07782086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782086.